The study examined the therapeutic monitoring of daptomycin (an antibiotic) in 280 critically ill patients hospitalized in the intensive care unit from January 2010 to July 2023. The research found that daptomycin levels were often too low in these patients - 62 patients (54.4%) had the first measured trough level below 10 mg/l, the required therapeutic level. Although doctors increased the dose in 14 patients, their subsequent levels did not increase and remained at a median of 7.0 mg/L. Patients who underwent monitoring had a significantly higher frequency of dose escalation (28.8% vs. 13.1%) and fewer daptomycin-free days (5 days vs. 10 days) compared to patients without monitoring. Despite these differences, the incidence of adverse events (increased creatine kinase and eosinophil count) was not significantly different between groups. The study concluded that daptomycin levels are often low in critically ill patients and often do not increase after dose adjustment, while monitoring did not reduce the incidence of side effects.